PTC Therapeutics (PTCT) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $0.92
- Estimate
- $0.34
- Surprise
- +170.6%
- Revenue (period 2026-06-30)
- $360.5M
- Score at report (before → after)
- 6.0 → 6.5/10
Revenue source: xbrl.
How the report landed
PTC Therapeutics (PTCT) beat the $0.34 estimate with adjusted EPS of $0.92 — a large 170.6% upside surprise. TrendMatrix's engine moved from Sell (6.0/10) to Buy (Wait) at 6.5/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PTCT Hold at 6.6/10.
2 of the last 4 quarters beat the estimate; this quarter's +170.6% surprise compares with a -80.9% four-quarter average. Next scheduled report: 2027-02-18.
What supports the rating
- Sector modifier (Healthcare): +0.5
- Positive news sentiment (+0.60)
What argues against it
- Consecutive earnings misses (2)
- Below 200-MA, MA slope -2.8%/30d (confirmed downtrend)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $67.50
- Price target
- $90.42
- Stop
- $62.78
- Upside to target
- +34.0%
- Reward-to-risk
- 2.6:1
Model outputs from TrendMatrix’s engine as of 2026-11-03 — shown for context, not personalized investment advice.
PTCT at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $5.09B
- P/E (fwd)
- 25.1
- 52-week range
- $58.80–$90.87
- Off 52-week high
- 25.7%
- RSI (14)
- 65
- Volume vs avg
- 0.81×
- Score today
- 6.6/10